MediWound Ltd. announced it will release its financial results for the third quarter ending September 30, 2026, on November 12, 2026. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. MediWound is known for its enzymatic therapeutics for tissue repair, including the FDA-approved product NexoBrid® and the investigational therapy EscharEx®. Investors and interested parties can access the webcast live or via replay on the company’s website.
MediWound's upcoming Q3 2026 financial results are set for release on November 12, 2026. For readers following the health sector, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced health-sector US stocks, 95 rose and 47 fell. Notable movers include Eli Lilly And Co (LLY) at USD 1,341.75 with a 1-day change of +4.11% and Pluang order activity of 29% Sell / 71% Buy, Amgen, Inc. (AMGN) at USD 468.17 with +3.62% change and 18% Sell / 82% Buy, and Vertex Pharmaceuticals Incorporated (VRTX) at USD 547.98 with +3.45% change and 56% Sell / 44% Buy.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
